drugset / Trial / NCT06565871

A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea

NCT06565871

Phase 2 Not yet recruiting 108 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect and safety of HRS9531 Injection in Obese Subjects with Obstructive Sleep Apnea

Timeline

Start
2024-08
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown Subcutaneous

Indications

No indication recorded.